Renal Cell Carcinoma (RCC)NCT07497958
Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy
A study testing Ischemic preconditioning and NO ischemic preconditioning in people with Renal Cell Carcinoma (RCC) and Renal Function Abnormal, run by Sun Yat-sen University at 1 site in China.
Trial summary
It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Renal Cell Carcinoma (RCC), Renal Function Abnormal
- What is being tested?
- Ischemic preconditioning and NO ischemic preconditioning
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 174 participants
- Where
- 1 siteChina
- Study dates
- 1 Apr 2026to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who are scheduled to undergo partial nephrectomy, with no specific surgical procedure limitation, including laparoscopic surgery, robot-assisted surgery, and open surgery
- Aged 18 to 80
- Possess good organ function status: sufficient organ function (based on the normal values of the clinical trial center)
- Blood routine test: WBC≥3.5×10^9/L, absolute neutrophil count ≥1.5×10^9/L, PLT≥75.0×10^9/L, HGB≥80g/L;
- Liver function: Total bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;
Who cannot join
- The anesthesiologist assesses that the patient cannot tolerate general anesthesia surgery
- Individuals with severe cardiovascular and cerebrovascular diseases, uncontrolled hypertension, and diabetes
- Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m²
- Horseshoe kidney
- Solitary kidney
- Pregnant women
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000
About this study
Official title: Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy: a Randomized Controlled Clinical Study
It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy.
Read the detailed description
The study cohort was randomly divided into two groups. One group received remote ischemic preconditioning one day before partial nephrectomy, while the other group underwent partial nephrectomy directly. The degree of acute renal injury on the operated side was compared between the two groups
- Being tested
- Ischemic preconditioning, NO ischemic preconditioning
- Keywords
- Renal Function Abnormal, Acute kidney injury, Partial nephrectomy, Ischemic preconditioning
- Medical subject headings
- Carcinoma, Renal Cell, Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ischemic preconditioningProcedure or surgery
One day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy
NO ischemic preconditioningProcedure or surgery
Routine partial nephrectomy
| Study group | Role | What they receive |
|---|---|---|
| Experimental : Ischemic preconditioning | Experimental | One day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy Receives: Procedure: Ischemic preconditioning |
| Comparator : No ischemic preconditioning | Active comparator | Routine partial nephrectomy Receives: Procedure: NO ischemic preconditioning |
What is being measured
The primary outcome is the main question the study is designed to answer.
AIRD spectrum score based on the patient's preoperative creatinine level and postoperative peak creatinine level
The AIRD spectrum score was defined as: (observed peak SCr - SCr ideal-peak)/(SCr worstcase-peak - SCr ideal-peak） The range of this indicator should be between 0 and 1, with 0 and 1 representing two extreme situations. 0 indicates that the kidney on the operated side is completely undamaged, while 1 indicates that the kidney on the operated side has completely lost its function.
Measured: 2 weeks after partial nephrectomy
Secondary outcomes (1)
Recovery from ischemia based on the changes in creatinine levels before and after the partial nephrectomy and volume retention rate after the partial nephrectomy
Recovery from ischemia = (%GFR saved)/(%parenchymal mass preserved)
Measured: 3 month after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2026
- Study start1 Apr 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal Cell Carcinoma (RCC)Studies of the same condition, open and under way.
- More trials run by Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study cohort was randomly divided into two groups. One group received remote ischemic preconditioning one day before partial nephrectomy, while the other group underwent partial nephrectomy directly. The degree of acute renal injury on the operated side was compared between the two groups
- Masking
- None (open label)
- Enrolment
- 174 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ZHOU FANGJIAN, Sun Yat-sen University
- Investigators
- Fangjian Zhou, professor, Principal investigator, Sun Yat-sen University Cancer Center (SYSUCC)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07497958
- Sponsor's protocol ID
- B2026-114
- Status last verified
- Mar 2026
- First submitted
- 15 Mar 2026
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy: a Randomized Controlled Clinical Study
- ClinicalTrials.gov ID
- NCT07497958
- Acronym / sponsor ID
- B2026-114
- Keywords
- Renal Function Abnormal, Acute kidney injury, Partial nephrectomy, Ischemic preconditioning
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 174 participants (estimated)
- Lead sponsor
- Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 27 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy.
Detailed description
The study cohort was randomly divided into two groups. One group received remote ischemic preconditioning one day before partial nephrectomy, while the other group underwent partial nephrectomy directly. The degree of acute renal injury on the operated side was compared between the two groups
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The study cohort was randomly divided into two groups. One group received remote ischemic preconditioning one day before partial nephrectomy, while the other group underwent partial nephrectomy directly. The degree of acute renal injury on the operated side was compared between the two groups
| Arm | Type | Receives |
|---|---|---|
| Experimental : Ischemic preconditioning | Experimental | Procedure: Ischemic preconditioningOne day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy |
| Comparator : No ischemic preconditioning | Active comparator | Procedure: NO ischemic preconditioningRoutine partial nephrectomy |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients who are scheduled to undergo partial nephrectomy, with no specific surgical procedure limitation, including laparoscopic surgery, robot-assisted surgery, and open surgery
- Aged 18 to 80
- Possess good organ function status: sufficient organ function (based on the normal values of the clinical trial center)
Key exclusion criteria (6 listed)
- The anesthesiologist assesses that the patient cannot tolerate general anesthesia surgery
- Individuals with severe cardiovascular and cerebrovascular diseases, uncontrolled hypertension, and diabetes
- Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m²
- Horseshoe kidney
- Solitary kidney
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ischemic preconditioningOne day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy | Procedure or surgery | Experimental : Ischemic preconditioning |
| NO ischemic preconditioningRoutine partial nephrectomy | Procedure or surgery | Comparator : No ischemic preconditioning |
Primary outcome
AIRD spectrum score based on the patient's preoperative creatinine level and postoperative peak creatinine level
Time frame: 2 weeks after partial nephrectomy
The AIRD spectrum score was defined as: (observed peak SCr - SCr ideal-peak)/(SCr worstcase-peak - SCr ideal-peak） The range of this indicator should be between 0 and 1, with 0 and 1 representing two extreme situations. 0 indicates that the kidney on the operated side is completely undamaged, while 1 indicates that the kidney on the operated side has completely lost its function.
1 secondary outcome
Recovery from ischemia based on the changes in creatinine levels before and after the partial nephrectomy and volume retention rate after the partial nephrectomy
Time frame: 3 month after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Renal Cell Carcinoma (RCC)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 2
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Localized Clear Cell Renal Cell Carcinoma
Active, not recruitingPhase 1/2
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Fangjian Zhou, professor principal investigator
Sun Yat-sen University Cancer Center (SYSUCC)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ischemic preconditioning and NO ischemic preconditioning in people with Renal Cell Carcinoma (RCC) and Renal Function Abnormal, run by Sun Yat-sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fangjian Zhou, professor (020-87343865, zhoufj@sysucc.org.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AIRD spectrum score based on the patient's preoperative creatinine level and postoperative peak creatinine level (time frame: 2 weeks after partial nephrectomy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.